In-silico studies for the development of novel RET inhibitors for cancer treatment

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2021 · 109.5K citations · Full text

RET, ROS1 and ALK fusions in lung cancer

Kengo Takeuchi, Manabu Soda, Yuki Togashi et al. · Nature Medicine · 2012 · 1.3K citations

Oncology, Medicine, Cancer Genetics +4

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Scott M. Wilhelm, Jacques Dumas, Lila Adnane et al. · International Journal of Cancer · 2010 · 1.3K citations · Full text

Tyrosine Kinase, Pathology, Pharmacotherapy +18

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text

Angiogenesis, Novel Met, Medicine +13

PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching

Steven L. Dixon, Alexander M. Smondyrev, Shashidhar N. Rao · Chemical Biology & Drug Design · 2006 · 677 citations · Full text

Drug Target, Hit Identification, Novel Approach +27